REFERENTIES: (recent wetenschappelijk, peer reviewed werk)
(1). D.I. Abrams, H.P. Vizoso, S.B. Shade, C. Jay, M.E. Kelly en N.L. Benowitz (2007). Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study. Clin Pharmacol Ther 82: 572-578.
(2). Manuel Guzman (2003). Cannabinoids: potential anticancer agents. Nature 3: 745-755.
(3). Robert Melamede (2005). Harm reduction-the cannabis paradox. Harm Reduct J 2: 17.
(4). M. Salazar, A. Carracedo, Í.J. Salanueva, S. Hernández-Tiedra, M. Lorente, A. Egia, P. Vázquez, C. Blázquez, S. Torres, S. García, J. Nowak, G.M. Fimia, M. Piacentini, F. Cecconi, P.P. Pandolfi, L. González-Feria, J.L. Iovanna, M. Guzmán, P. Boya en G. Velasco (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372.
(5). J.P. Marcu, R.T. Christian, D. Lau, A.J. Zielinski, M.P. Horowitz, J. Lee, A. Pakdel, J. Allison, C. Limbad, D.H. Moore, G.L. Yount, P.-Y. Desprez en S.D. McAllister (2010). Cannabidiol enhances the inhibitory effects of ?9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
(6) A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira en F.S. Guimarães (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
(7). R.J. McKallip, C. Lombard, M. Fisher, B.R. Martin, S. Ryu, S. Grant, P.S. Nagarkatti en M. Nagarkatti (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627-634.
(8). M.L. Casanova, C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, J.W. Huffman, J.L. Jorcano en M. Guzman (2003). Inhibition of skin tumor growth and angiogenisis in vivo by activation of cannabinoid receptors J Clin Invest 111: 43-50.
(9). G. Portella, C. Laezza, P. Laccetti, L. De Petrocellis, V. Di Marzo en M. Bifulco (2003. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773.
(10). A. Ligresti, T. Bisogno, I. Matias, L. De Petrocellis, M.G. Cascio, V. Cosenza, G. D'argenio, G. Scaglione, M. Bifulco, I. Sorrentini en V. Di Marzo (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687.
(11). A. Ligresti, A.S. Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis, C. Laezza, G. Portella, M. Bifulco en V. Di Marzo (2006). Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. JPET 318: 1375-1387.
(12). M. Mimeault, N. Pommery, N. Wattez, C. Bailly en J.P. Hénichart (2003). Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1-12.
(13). P. Nagarkatti, R. Pandey, S.A. Rieder, V.L. Hegde en M. Nagarkatti (2009). Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1: 1333-1349.
(14). Robert Ramer en Burkhard Hinz (2007). Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1. JNCI J Natl Cancer Inst 100: 59-69.
(15). T.C. Wu, D.P. Tashkin, B. Djahed en J.E. Rose (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 318: 347-351.
(16). John D. Minna (2003). Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest 111: 31-33.
(17). B. Gardner,L.X. Zhu, S. Sharma, D.P. Tashkin en S.M. Dubinett (2003). Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 17: 2157-2159.
(18). S. Sidney, C.P. Jr. Quesenberry, G.D. Friedman, I.S. Tekawa (1997). Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8: 722-728.
(19). M. Hashibe, K. Straif, D.P. Tashkin, H. Morgenstern, S. Greenland, en Z.F. Zhang (2005). Epidemiologic review of marijuana use and cancer risk. Alcohol 35: 265-275.
(20). M. Hashibe, H. Morgenstern, Y. Cui, D.P. Tashkin, Z.-F. Zhang, W. Cozen, T.M. Mack en S. Greenland (2006). Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results of a Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev 15: 1829.
(21). S. Aldington, M. Harwood, B. Cox, M. Weatherall, L. Beckert, A. Hansell, A. Pritchard, G. Robinson en R. Beasley (2008). On behalf of the Cannabis and Respiratory Disease Research Group Cannabis use and risk of lung cancer: a case–control study. Eur Respir J 31: 280-286.
(22). R.A. Sewell, A.J. Cohn en M.C. Chawarski (2008). Doubts about the role of cannabis in causing lung cancer. Eur Respir J 32: 815-816.
(23). R. Singh, J. Sandhu, B. Kaur, T. Juren, W.P. Steward, D. Segerba en P.B. Farmer (2009). Evaluation of the DNA Damaging Potential of Cannabis Cigarette Smoke by the Determination of Acetaldehyde Derived N2-Ethyl-2'-deoxyguanosine Adducts. Chem Res Toxicol 22: 1181-1188.
(24). C. Blazquez, M.L. Casanova, A. Planas, T.G. Del Pulgar, C. Villanueva, M.J. Fernandez-Acenero, J. Aragones, J.W. Huffman, J.L. Jorcano en M. Guzman (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17: 529-531.
(25). M. Guzmán, M.J. Duarte, C. Blázquez, J. Ravina, M.C. Rosa, I. Galve-Roperh, C. Sánchez, G. Velasco en L. González-Feria (2006). A pilot clinical study of ?9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal Of Cancer 95: 197-203.